

Drug Policy

Policy:	Tavalisse (fostamatinib)	Annual Review Date: 07/18/2024 Last Revised Date: 07/18/2024
----------------	---------------------------------	---

OVERVIEW

Tavalisse, a tyrosine kinase inhibitor with demonstrated activity against spleen tyrosine kinase, is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The major metabolite of Tavalisse, R406, inhibits signal transduction by Fc-activating receptors and B-cell receptor. The R406 metabolite reduces antibody-mediated destruction of platelets. The safety and efficacy of Tavalisse have not been established in pediatric patients. Use of Tavalisse is not recommended for patients < 18 years of age because adverse events on actively growing bones were observed in nonclinical studies. In subchronic, chronic, and carcinogenicity studies involving Tavalisse, chondrodystrophy of the femoral head was observed in rodents. In a study involving juvenile rabbits, growth plate dysplasia was noted in the proximal femur and femoro-tibial joint, and bone marrow cellularity was reduced in the femur and sternum.

POLICY STATEMENT

This policy involves the use of Tavalisse. Prior authorization is recommended for pharmacy benefit coverage of Tavalisse. Approval is recommended for those who meet the conditions of coverage in the **Criteria and Initial/Extended Approval** for the diagnosis provided. **Conditions Not Recommended for Approval** are listed following the recommended authorization criteria. Requests for uses not listed in this policy will be reviewed for evidence of efficacy and for medical necessity on a case-by-case basis.

Because of the specialized skills required for evaluation and diagnosis of patients treated with Tavalisse as well as the monitoring required for adverse events and long-term efficacy, initial approval requires Tavalisse be prescribed by or in consultation with a physician who specializes in the condition being treated. All approvals for initial therapy are provided for the initial approval duration noted below; if reauthorization is allowed, a response to therapy is required for continuation of therapy unless otherwise noted below.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Tavalisse is recommended in those who meet the following criteria:

1. **Chronic Immune Thrombocytopenia (ITP), Initial Therapy/New Starts**
Criteria. *Patient must meet the following criteria (A, B, C, D and E):*
 - A. The patient is 18 years of age or older; AND
 - B. The agent is prescribed by, or in consultation with a hematologist; AND
 - C. The patient has tried corticosteroids or IVIG, unless contraindicated; AND
 - D. The patient has tried Doptelet, or Doptelet is contraindicated AND

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>

Drug Policy

E. The patient meets one of the following (i or ii):

- i. The patient has a platelet count $< 30 \times 10^9/L$ ($< 30,000/\mu L$): OR
- ii. The patient has a platelet count $< 50 \times 10^9/L$ ($< 50,000/\mu L$) and according to the prescriber the patient is at an increased risk of bleeding; (e.g., upcoming medical or dental procedure with expected blood loss; peptic ulcer disease; hypertension; anticoagulation therapy; or profession or lifestyle that predisposes patient to trauma, such as construction worker or plays contact sports).

2. **Patient is Currently Receiving Tavalisse**

Criteria. *Approve if the initial therapy criteria and the following criteria are met.*

- A. According to the prescriber the patient demonstrates a beneficial clinical response (e.g., increased platelet counts);
AND
- B. The patient remains at risk for bleeding complications.

Initial Approval/ Extended Approval.

A) *Initial Approval:* 90 days

B) *Extended Approval:* 365 days

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Tavalisse has not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval for the following conditions. (Note: This is not an exhaustive list of Conditions Not Recommended for Approval).

1. **B-Cell Lymphomas.** Tavalisse has been investigated in patients with various B-cell lymphomas (e.g., non-Hodgkin's lymphoma, diffuse large B-cell lymphoma [DLBCL]). Many other therapies are available for this use.
2. **Rheumatoid Arthritis.** Tavalisse has been studied in patients with rheumatoid arthritis. Other well-established therapies are available.
3. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

Documentation Requirements:

The Company reserves the right to request additional documentation as part of its coverage determination process. The Company may deny reimbursement when it has determined that the drug provided or services performed were not medically necessary, investigational or experimental, not within the scope of benefits afforded to the member and/or a pattern of billing or other practice has been found to be either inappropriate or excessive. Additional documentation supporting medical necessity for the services provided must be made available upon request to the Company.

Drug Policy

Documentation requested may include patient records, test results and/or credentials of the provider ordering or performing a service. The Company also reserves the right to modify, revise, change, apply and interpret this policy at its sole discretion, and the exercise of this discretion shall be final and binding.

REFERENCES

1. Tavalisse [prescribing information]. South San Francisco, CA: Rigel Pharmaceutical; April 2018.
2. Fostamatinib. In: DRUGDEX (online database). Truven Health Analytics; Greenwood Village, CO. Last updated 26 November 2018. Accessed on 14 May 2019.
3. Bussel J, Arnold DM, Grossbard E, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. *Am J Hematol*. 2018 April 26. [Epub ahead of print].
4. Bussel JB, Arnold DM, Cooper N, et al. Long-term maintenance of platelet responses in adult patients with persistent/chronic immune thrombocytopenia treated with fostamatinib: 1-year efficacy and safety results. *Blood*. 2017;130(Suppl 1):16. Available at: http://www.bloodjournal.org/content/130/Suppl_1/16. Accessed on 13 May 2018.
5. Newland A, Lee JE, McDonald V, Bussel JB. Fostamatinib for persistent/chronic adult immune thrombocytopenia. *Immunotherapy*. 2018;10(1):9-25.
6. Genovese MC, van der Heijde DM, Keystone EC, et al. A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor- α antagonist. *J Rheumatol*. 2014;41(11):2120-2128.
7. Weinblatt ME, Genovese MC, Ho M, et al. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: result from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. *Arthritis Rheumatol*. 2014;66(12):3255-3264.
8. Weinblatt ME, Kavanaugh A, Genovese MC, et al. An oral spleen tyrosine kinase (SYK) inhibitor for rheumatoid arthritis. *N Engl J Med*. 2010;363(14):1303-1312.
9. Taylor PC, Genovese MC, Greenwood M, et al. OSKIRA-4: a Phase IIb randomized, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy. *Ann Rheumat Dis*. 2015;74(12):2123-2129.
10. Kumwar S, Davkota AR, Ghimire DK. Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials. *Rheumatol Int*. 2016;36(8):1077-1087.
11. Flinn IW, Bartlett NL, Blum KA, et al. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). *Eur J Cancer*. 2016;54:11-17.
12. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. *Blood*. 2010;115(13):2578-2585.
13. Neunert C, Lim W, Crowther M et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. *Blood*. 2011;117(16):4190-4207.
14. Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. *Blood*. 2017;129(21):2829-2835.
15. Nplate® injection for subcutaneous use [prescribing information]. Thousand Oaks, CA: Amgen; October 2017.
16. Promacta® tablets and oral suspension [prescribing information]. East Hanover, NJ: Novartis; October 2017.
17. Grace RF, Neunert C. Second-line therapies in immune thrombocytopenia. *Hematology Am Soc Hematol Educ Program*. 2016;2016(1):698-706.